We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+46.69%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.05B
AUM Growth
+$352M
Cap. Flow
-$16.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
43.96%
Holding
116
New
16
Increased
40
Reduced
31
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$31.1M
2
AVLN
Avalyn Pharma
AVLN
+$19.1M
3
PBLS
Parabilis Medicines Inc
PBLS
+$16M
4
COAG
Hemab Therapeutics
COAG
+$15.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.7M
2
ACLX
Arcellx
ACLX
+$19.5M
3
ELVN icon
Enliven Therapeutics
ELVN
+$15.4M
4
RVMD icon
Revolution Medicines
RVMD
+$15.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
51
Ardelyx
ARDX
$984M
$11.4M 0.56%
2,241,769
-57,704
-3% -$352K
INSP icon
52
Inspire Medical Systems
INSP
$1.78B
$10.9M 0.53%
244,000
+112,200
+85% +$5.32M
BBIO icon
53
BridgeBio Pharma
BBIO
$15B
$10.8M 0.53%
144,750
+16,500
+13% +$1.16M
ALKS icon
54
Alkermes
ALKS
$7.95B
$10.5M 0.51%
199,811
+15,825
+9% +$618K
SMMT icon
55
Summit Therapeutics
SMMT
$11B
$10.4M 0.51%
715,000
+5,000
+0.7% +$88.7K
AZTA icon
56
Azenta
AZTA
$1.44B
$10.3M 0.5%
403,000
-166,100
-29% -$3.72M
INDV icon
57
Indivior Pharmaceuticals
INDV
$4.12B
$10.1M 0.49%
245,500
+45,500
+23% +$1.65M
SYK icon
58
Stryker
SYK
$127B
$9.13M 0.45%
29,000
+14,200
+96% +$4.47M
AMLX icon
59
Amylyx Pharmaceuticals
AMLX
$3.87B
$8.98M 0.44%
499,764
– –
CAI
60
Caris Life Sciences
CAI
$7.24B
$8.69M 0.42%
487,500
-75,500
-13% -$1.35M
OMDA
61
Omada Health Inc
OMDA
$1.45B
$8.19M 0.4%
373,000
-168,000
-31% -$2.68M
CMPX icon
62
Compass Therapeutics
CMPX
$432M
$7.72M 0.38%
3,524,929
+219,621
+7% +$648K
IMNM icon
63
Immunome
IMNM
$3.13B
$7.37M 0.36%
347,666
– –
FOCL
64
EDAP TMS S.A.
FOCL
$198M
$7.18M 0.35%
1,386,000
+8,000
+0.6% +$32.7K
PHR icon
65
Phreesia
PHR
$751M
$7.17M 0.35%
696,900
+96,500
+16% +$896K
OMER icon
66
Omeros
OMER
$1.35B
$6.83M 0.33%
+718,499
New +$8.55M
DFTX
67
Definium Therapeutics
DFTX
$5.51B
$6.74M 0.33%
+143,187
New +$3.54M
CORT icon
68
Corcept Therapeutics
CORT
$12.3B
$6.26M 0.31%
72,000
+21,750
+43% +$1.31M
JANX icon
69
Janux Therapeutics
JANX
$1.1B
$5.64M 0.28%
367,009
– –
MOBI
70
Mobia Medical
MOBI
$378M
$5.6M 0.27%
+418,200
New +$5.42M
RCUS icon
71
Arcus Biosciences
RCUS
$3.72B
$5.55M 0.27%
180,000
– –
TMO icon
72
Thermo Fisher Scientific
TMO
$230B
$5.01M 0.24%
10,000
– –
TRVI icon
73
Trevi Therapeutics
TRVI
$2.39B
$4.85M 0.24%
+260,000
New +$3.78M
SION
74
Sionna Therapeutics
SION
$265M
$4.37M 0.21%
99,429
– –
CVS icon
75
CVS Health
CVS
$119B
$4.14M 0.2%
40,000
– –
1 2
3
4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rock Springs Capital Management held 116 positions worth $2.05B, up 21% from $1.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rock Springs Capital Management's Q2 2026 filing shows 16 new, 40 increased, 31 reduced and 12 closed positions. Its largest new stake was Avalyn Pharma: 662,918 shares worth $21.8M. The largest sale was argenx, an estimated $37.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Rock Springs Capital Management's largest Q2 2026 buy was Avalyn Pharma: 662,918 shares worth $21.8M.
  • Rock Springs Capital Management added most to Travere Therapeutics in Q2 2026, an estimated $31.1M increase.
  • Rock Springs Capital Management's biggest Q2 2026 reduction was argenx, cutting an estimated $37.7M.
  • Rock Springs Capital Management fully exited Arcellx in Q2 2026, selling an estimated $19.5M.
  • Rock Springs Capital Management's ten largest holdings make up 44% of its $2.05B portfolio in Q2 2026.
  • Rock Springs Capital Management opened 16 new positions and closed 12 in Q2 2026.
  • Rock Springs Capital Management's portfolio value rose 21% quarter-over-quarter to $2.05B.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.